Skip to main content
. 2021 Jan 1;11(2):824–840. doi: 10.7150/thno.49600

Figure 4.

Figure 4

The anti-tumor effects of W2014-S in human lung cancer cell xenografts and PDX models in vivo.Nu/nu mice were bearing A549 xenografts or PDX and treated with W2014-S (i.p. 5 or 15 mg/kg/day) for 21 d. (A) Tumor volume of A549 xenografts. Data were expressed as mean ± SEM, n=6. *P < 0.05, **P < 0.01, ***P < 0.001. (B) Tumor weights and size of A549 xenografts. Data were expressed as mean ± SEM, n=6. *P < 0.05, **P < 0.01, ***P < 0.001. (C) Tumor volume of PDX. Data were expressed as mean ± SEM, n=6. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Tumor weights and size of PDX. Data were expressed as mean ± SEM, n=6. *P < 0.05, **P < 0.01, ***P < 0.001. (E-F) The protein levels of pY705-STAT3 and Ki-67 of A549 xenografts and PDX of mice was detected by IHC and scale bar was 150 μm. (G-H) The changes of pY705-STAT3, STAT3, c-Myc, Bcl-xL and Bcl-2 levels of A549 xenografts and PDX were measured by western blot.